Rein Therapeutics to be Acquired by 03 Life Sciences
Ticker: RNTX · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, corporate-action
TL;DR
Rein Therapeutics is being bought by 03 Life Sciences, deal expected to close Q3 2025.
AI Summary
Rein Therapeutics, Inc. announced on June 10, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions. This acquisition follows Rein Therapeutics' name change from Aileron Therapeutics, Inc. on March 29, 2024.
Why It Matters
This acquisition signifies a consolidation within the pharmaceutical sector, potentially impacting Rein Therapeutics' drug development pipeline and future market presence.
Risk Assessment
Risk Level: medium — Acquisition news can introduce volatility as market participants assess the deal's terms and future implications.
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- 03 Life Sciences (company) — Acquiring entity
- Aileron Therapeutics, Inc. (company) — Former company name
- June 10, 2025 (date) — Date of earliest event reported
- third quarter of 2025 (date) — Expected closing period for acquisition
FAQ
What is the nature of the event reported in this 8-K filing?
Rein Therapeutics, Inc. reported an 'Other Event' concerning a definitive agreement for its acquisition by 03 Life Sciences.
Who is acquiring Rein Therapeutics, Inc.?
03 Life Sciences is acquiring Rein Therapeutics, Inc.
When is the acquisition expected to close?
The acquisition is expected to close in the third quarter of 2025.
Has Rein Therapeutics, Inc. undergone any recent name changes?
Yes, Rein Therapeutics, Inc. was formerly known as Aileron Therapeutics, Inc., with a name change effective March 29, 2024.
What is the principal executive office address for Rein Therapeutics, Inc.?
The principal executive offices are located at 12407 N. Mopac Expy. Suite 250 #390, Austin, Texas 78758.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Rein Therapeutics, Inc. (RNTX).